2021 ODS/WSDA PNW Joint Dermatology Meeting Program Evaluation

Home of the Pacific Northwest Dermatological Conference

Home of the Pacific Northwest Dermatological Conference

In-office procedures for hidradenitis suppurativa - Steve Daveluy, MD, FAAD

Case-based medical management of hidradenitis suppurativa - Steve Daveluy, MD, FAAD

Cases in Pediatric Dermatology - Julie Dhossche, MD

A Talk on Advocacy and Health Literacy - Julie Dhossche, MD

Human Inflammation and Cardiometabolic Diseases: Lessons Learned from Psoriasis - Nehal Mehta, MD, MSCE, FAHA

Progress in Inflammatory Nail Disorders - Adam Rubin, MD

Optimizing Nail Surgical Techniques - Adam Rubin, MD

Vasculitis Update 2021 - Kathy Schwarzenberger, MD

Mast Cell Activation Syndrome: What the Dermatologist May See - Kathy Schwarzenberger, MD

Mistakes I have Made Part I: The World of Genodermatoses - Virginia Sybert, MD

Mistakes I have Made Part II: The World of Genodermatoses - Virginia Sybert, MD

American Academy of Dermatology Update - Bruce Thiers, MD, FAAD

Adverse Effects of Immune Checkpoint Inhibitors - Bruce Thiers, MD, FAAD

What Is That and Why Does It Matter? Dermatopathology Updates for Clinical Dermatology - Valencia Thomas, MD

From Tumors to Fillers: What’s New In Cutaneous Surgery - Valencia Thomas, MD

Understanding the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus - Jenna Thomason, MD, MPH

Preventative Medicine for the Dermatology Patient on Immunomodulatory or Immunosuppressive Therapy - Jenna Thomason, MD, MPH

Conference

Credit Claim

In-office procedures for hidradenitis suppurativa - Steve Daveluy, MD, FAAD

Case-based medical management of hidradenitis suppurativa - Steve Daveluy, MD, FAAD

Cases in Pediatric Dermatology - Julie Dhossche, MD

A Talk on Advocacy and Health Literacy - Julie Dhossche, MD

Human Inflammation and Cardiometabolic Diseases: Lessons Learned from Psoriasis - Nehal Mehta, MD, MSCE, FAHA

Progress in Inflammatory Nail Disorders - Adam Rubin, MD

Optimizing Nail Surgical Techniques - Adam Rubin, MD

Vasculitis Update 2021 - Kathy Schwarzenberger, MD

Mast Cell Activation Syndrome: What the Dermatologist May See - Kathy Schwarzenberger, MD

Mistakes I have Made Part I: The World of Genodermatoses - Virginia Sybert, MD

Mistakes I have Made Part II: The World of Genodermatoses - Virginia Sybert, MD

American Academy of Dermatology Update - Bruce Thiers, MD, FAAD

Adverse Effects of Immune Checkpoint Inhibitors - Bruce Thiers, MD, FAAD

What Is That and Why Does It Matter? Dermatopathology Updates for Clinical Dermatology - Valencia Thomas, MD

From Tumors to Fillers: What’s New In Cutaneous Surgery - Valencia Thomas, MD

Understanding the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus - Jenna Thomason, MD, MPH

Preventative Medicine for the Dermatology Patient on Immunomodulatory or Immunosuppressive Therapy - Jenna Thomason, MD, MPH

Conference

Credit Claim

Aug. 13-15, 2021

In-office procedures for hidradenitis suppurativa

Steve Daveluy, MD, FAAD

Comments

Having the session, please rate your ability to:

	Significantly Increased	Neutral	Significantly Decreased
Decide which in-office procedures are appropriate for patients with hidradenitis suppurativa
Successfully perform deroofing and inralesional steroid injection for hidradenitis suppurativa

Case-based medical management of hidradenitis suppurativa

Steve Daveluy, MD, FAAD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Describe patient and disease characteristics that guide treatment decisions in hidradenitis suppurativa
Provide a range of medical therapies to patients with hidradenitis suppurativa

Cases in Pediatric Dermatology

Julie Dhossche, MD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Demonstrate an improved knowledge base of various pediatric cutaneous disorders and their treatment options

A Talk on Advocacy and Health Literacy

Julie Dhossche, MD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Understand the role of health literacy in patient care and outcomes
Recognize the role of the physician as a patient advocate in various modalities

Human Inflammation and Cardiometabolic Diseases: Lessons Learned from Psoriasis

Nehal Mehta, MD, MSCE, FAHA

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Psoriasis is a systemic inflammatory disease
Cardiometabolic diseases include cardiovascular diseases and diseases associated with obesity, including dyslipidemia and diabetes

Progress in Inflammatory Nail Disorders

Adam Rubin, MD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Describe the evaluation and treatment of patients with trachyonychia
Describe advances in the diagnosis and treatment of nail unit lichen planus.

Optimizing Nail Surgical Techniques

Adam Rubin, MD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Describe anesthetic techniques for optimal pain control for nail unit surgery
Describe surgical approaches to longitudinal erythronychia

Vasculitis Update 2021

Kathy Schwarzenberger, MD

Comments

Having the session, please rate your ability to:

Mast Cell Activation Syndrome: What the Dermatologist May See

Kathy Schwarzenberger, MD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Be familiar with spectrum of diseases associated with mast cell activation
Understand the differences between primary and secondary mast cell activation disorders

Mistakes I have Made Part I: The World of Genodermatoses

Virginia Sybert, MD

Comments

Having the session, please rate your ability to:

Mistakes I have Made Part II: The World of Genodermatoses

Virginia Sybert, MD

Comments

Having the session, please rate your ability to:

American Academy of Dermatology Update

Bruce Thiers, MD, FAAD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Be familiar with American Academy of Dermatology stategic objectives
Be aware of policies and priorities to accomplish these objectives

Adverse Effects of Immune Checkpoint Inhibitors

Bruce Thiers, MD, FAAD

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Describe the mechanism of action of the two major classes of immune checkpoint inhibitors
Identify the side effects of immune checkpoint inhibitors

What Is That and Why Does It Matter? Dermatopathology Updates for Clinical Dermatology

Valencia Thomas, MD

Comments

Having the session, please rate your ability to:

From Tumors to Fillers: What’s New In Cutaneous Surgery

Valencia Thomas, MD

Comments

Having the session, please rate your ability to:

Understanding the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus

Jenna Thomason, MD, MPH

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Interpert results of ANA testing
Employ these criteria as a guide to determine the likelihood of SLE in your patient with suspected or confirmed cutanious lupus

Preventative Medicine for the Dermatology Patient on Immunomodulatory or Immunosuppressive Therapy

Jenna Thomason, MD, MPH

Comments

Having the session, please rate your ability to:

	Significantly increased	Neutral	Significantly decreased
Recall immunizations recommended for patients on immunosuppression
Discuss steps we can take to prevent glucocorticoid-induced osteoporosis

Having attended this conference, how did we meet the following objectives listed out?

List 2-3 strategies you plan to implement as a result of attending the conference.

A "commercial interest" is defined as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Among the exemptions to this definition are government organizations, non-health care related companies and non-profit organizations that do not advocate for commercial interests. Was the presentation fair, balanced, and free of commercial bias?

Yes

If no, please explain why.

What potential barriers do you anticipate encountering as you incorporate what you learned at this activity?

Is there is anything else you would like us to know?

Name(Required)

First Last Credentials

Number of Credits Claimed (9.75 available)(Required)

Please enter a number less than or equal to 9.75.

The WSMA designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians should claim credit in 15-minute increments (i.e. 0.25 credits).

Satisfactory

Implement updates in medical and surgical dermatology in clinical practice.

Describe changes to the AAD and clinical practice since the onset of the Covid pandemic.

Adjust clinical practice in accordance with the above changes.

Implement updates in medical and surgical dermatology in clinical practice.